ArticleFEMS yeast research2026
Overexpression of the MAPK transcription factor gene MSS11 enhances ethanol biosynthesis in Saccharomyces cerevisiae via coordinated metabolic and stress-response reprogramming.
Article in FEMS yeast research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bioethanol is a pivotal sustainable alternative to fossil fuels. Saccharomyces cerevisiae is the primary microorganism for its industrial production. Enhancing the fermentative performance of S. cerevisiae is crucial for sustainable bioethanol production. To systematically enhance the fermentative capacity of yeast, this study employed targeted genetic engineering to overexpress MSS11-a principal transcription factor within the mitogen-activated protein kinase (MAPK) signaling cascade. The resultant recombinant strain, Eng-1, demonstrated a marked 23.9% enhancement in final ethanol titer (18.94 g/l vs. 15.29 g/l) and a commensurate 23.8% improvement in yield coefficient (0.473 vs. 0.382 g ethanol per g glucose) relative to the isogenic control strain Eng-0 under microaerobic batch fermentation. This phenotype was consistently validated in a distinct genetic background (JT139 derivative), underscoring the generalizable function of MSS11. Transcriptomic analysis revealed that MSS11 orchestrates a dual regulatory mechanism: it upregulates pyruvate-supplying pathway genes to enhance carbon flux toward ethanol, while concurrently activating a suite of genes involved in oxidative, osmotic, and ethanol stress tolerance to improve cellular robustness. These findings establish MSS11 as a novel and effective metabolic engineering target for yeast, and they elucidate its dual regulatory mechanism in coordinately enhancing carbon conversion and cellular robustness, thereby providing a strategic framework for constructing high-performance microbial cell factories for advanced biofuel production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.